- Home
- MLAB vs RGNX Comparison
MLAB vs RGNX Comparison
Compare MLAB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLAB | RGNX |
|---|---|---|
| Founded | 1982 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 461.9M | 418.1M |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MLAB | RGNX |
|---|---|---|
| Price | $100.34 | $9.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $94.00 | $28.75 |
| AVG Volume (30 Days) | 83.8K | ★ 572.1K |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | ★ 99.24 | 18.08 |
| EPS | ★ 1.95 | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | $6.07 | $50.15 |
| Revenue Next Year | $5.41 | $23.42 |
| P/E Ratio | $50.75 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $59.63 | $5.85 |
| 52 Week High | $128.55 | $16.19 |
Technical Indicators
Market Signals| Indicator | MLAB | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 71.63 | 57.67 |
| Support Level | $69.02 | $7.76 |
| Resistance Level | $103.73 | $10.08 |
| Average True Range (ATR) | 3.75 | 0.50 |
| MACD | 1.53 | 0.17 |
| Stochastic Oscillator | 97.59 | 89.45 |
Price Performance
Historical ComparisonAbout MLAB Mesa Laboratories Inc.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.